Product
SCB-2023
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
Phase 3, Multi-center, Observer-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of SCB-2023 Vaccine Administered as a Booster Dose to Adults Who Previously Received COVID-19 VaccineStatus: Withdrawn, Estimated PCD: 2023-08-17